Drug intelligence / Profile preview

JJH202301

Development stage: Preclinical
Lead developer: Jiangsu Jibeier Pharmaceutical
Modality: Small Molecules

Overview

JJH202301 is a small molecule drug candidate currently under development by Jiangsu Jibeier Pharmaceutical for the treatment of type 2 diabetes. As of early 2024, the compound is in the preclinical stage of development. While it is identified as a new chemical entity within the company's metabolic disease pipeline, specific details regarding its biological target or mechanism of action have not yet been publicly disclosed. It represents part of Jiangsu Jibeier's strategic expansion into the chronic disease market, alongside other metabolic candidates like Sangpanasine.

Beyond the preview

Go deeper on JJH202301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JJH202301.

Explore the full profile